About the Company
3BiotiX is an emerging start-up company specializing in innovative biofilm solutions. Our research focuses on antimicrobial medicinal treatments aimed at eliminating fungal and bacterial infections resistant to conventional treatments.
We are pioneering novel combination therapies to overcome infectious diseases by disarming the stubborn biofilms that cause recurrence and refractory symptoms.
Our leading development is an innovative drug combination for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a chronic vaginitis unresponsive to conventional treatments.
We are located in the Negev desert in southern Israel and the company is recognized and supported by the Israeli Innovation Authority.
3BiotiX originated from the research laboratory of Professor Doron Steinberg who leads the Biofilm Research Lab in the Hebrew University of Jerusalem.
Our current Project
Our current project focuses on transforming treatment for recurrent vulvovaginal candidiasis (RVVC), a chronic infection that afflicts millions of women globally.
Our innovative formulation combines 2 different ingredients. One has an anti-biofilm and antifungal effect and the second one will contribute to the balance of the vaginal microbiome by keeping a normal pH level in the vagina.
Our promising combination treatment is aiming to decrease the biofilm burden by 80%.
With an innovative platform and patient-centered mindset, our project holds a promise to revolutionize care for those stuck in cycles of chronic, hard-to-treat yeast infections.
We aim to restore quality of life by addressing biofilm persistence where current therapies fall short.
Our Portfolio
Our Vision
Our vision is to become a leading innovator in antimicrobial therapies by applying our anti-biofilm expertise.
We aim to develop best-in-class antimicrobial solutions that overcome resistance, providing more effective treatments for chronic and recurring infections.
The Team
I graduated as a medical doctor in 1992 from the Medical University of Lyon, France.
My expertise lies in advanced medical technologies, clinical validation, and go-to-market strategy.
In my previous role as Director of Business Development at Medtechnica, Israel’s top distributor of medical equipment and health services, I was responsible for driving growth and identifying new business opportunities.
I hold a BSc in Neuroscience, an MSc in Biotechnology, and an MBA.
I have extensive experience in pharmaceuticals and medical device development.
In my previous executive roles, I served as a COO (Orbix Medical), VP Clinical & Business development (Sol-Gel technologies) and as a Manager of Dermatology Operations (Arkin Holdings).
I hold a PhD in Neurosciences from Ben-Gurion University of the Negev, Israel.
I am experienced in different cell culture methods, animal models, biochemistry, and molecular biology techniqwues.
I am leading the scientific research at 3BiotiX to find innovative pharmaceutical solutions for the treatment of infectious diseases related to biofilms.
I have extensive experience in Business Development and key account management.
At 3BiotiX, I am accountable for arranging data related to sales figures and market research.
I am bridging between the CEO and the founders, assisting them in identifying new projects and opportunities.
Advisory Board
A senior physician at the Division of Obstetrics and Gynecology at the Sheba Medical Center, Associate Professor at the Sackler School of Medicine, Tel-Aviv University, ranked among the best physicians in Israel. He is the author of more than 250 scientific papers on the topics of endoscopic surgery and fertility problems.
Jacob Bornstein MD, MPA, is Professor and Past Chair of the Department of Obstetrics & Gynecology in Galilee Medical Center and Past Associate Dean of the Faculty of Medicine of the Bar-Ilan University, Israel; Honorary Professor, Buenos Aires University, School of Medicine, and Past President of the ISSVD.
He is the Editor-in-Chief of JLGTD, author of the book: “Vulvar Disease, breaking the myths”, ex-officio member of the ASCCP, chair of the IFCPC colposcopy nomenclature committee, and co-chair of the ISSVD terminology Committee.
Prof. Bornstein received the “Distinguished Scientific Award” of the American Colposcopy Society and the “ISSVD President award of Merit”, as well as the Israeli Society of Colposcopy and the Israeli Obstetrics and Gynecology Association Awards of Merit.
Dr. Shacham co-founded Karyopharm Therapeutics (Nasdaq- KPTI) in 2008 and has served as the Chief Scientific Officer since December 2012. She is a Senior executive with extensive experience in drug
discovery and development.
The Founders
Head of Biofilm Research Lab and a member of the academic committee of the Cannabis Research Center at the Hebrew University of Jerusalem.
An expert in biofilm formation mechanisms. Holds many patents of which one has evolved into a commercial product manufactured in Israel and sold worldwide (PerioChip).
Has been awarded several national and international research and personal awards.
Management, Business Development, Investor relations
Alon is an experienced entrepreneur, and the founder of a European retail company.
He worked in the past as a lawyer and holds a BA in finance.
Management, Business Development, Investor relations
Amir has 20 years of extensive experience as a CEO, a CFO, a board member, and an entrepreneur.
Amir is the founder and the owner of a CFO and M&A’s services company in Israel.
Our Partners
What is a Biofilm?
A biofilm is a community of microorganisms like bacteria that stick to surfaces and embed themselves in a slimy, glue-like substance they secrete. These complex colonies provide protection, allowing embedded cells to grow and reproduce.
Most biofilms host mixtures of multiple microbial species, along with non-living debris.
Biofilms can form on any moist surface – metals, plastics, rocks, medical implants, tissues, and more. Wherever moisture, nutrients, and surfaces meet – surfaces end up covered in biofilm communities.
Our Next Challenge
Leading Disruptive Antimicrobial Innovation
At 3BiotiX, we are pioneering novel biofilm-disrupting therapies to transform the treatment of chronic infections and address resistance challenges limiting current standards of care.
We have already demonstrated breakthrough clinical potential with our proprietary combinations, and we strive to discover innovative solutions for other conditions.
Developing an innovative antibiofilm treatment for bacterial vaginosis (BV).
Bacterial vaginosis is the most common cause of vaginal discharge among women of reproductive age.
BV prevalence varies across countries and population groups, but a recent systematic review and meta-analysis of the global BV prevalence among women of reproductive age ranged from 23 to 29%
BV is described by an imbalance in the vaginal microbiota where strictly and facultative anaerobic bacteria outgrow the lactic acid‐ and hydrogen peroxide‐producing Lactobacillus species. The species involved in BV are capable of growing and form a polymicrobial biofilm in the vaginal epithelium. The treatment of BV is usually performed using broad‐spectrum antibiotics, including metronidazole and clindamycin. However, these conventional treatments are associated with high recurrence rates. The BV polymicrobial biofilm may have an important role in the treatment outcome and is accounted as one of the factors for treatment failure.
Developing an innovative biofilm treatment for oral candidiasis
Oral candidiasis (or oral thrush) is a common opportunistic infection of the oral cavity caused by an overgrowth of Candida species, the mainly Candida albicans. Risk factors include impaired salivary gland function, drugs, dentures, high carbohydrate diet, and extremes of life, smoking, diabetes mellitus, Cushing’s syndrome, malignancies, and immunosuppressive conditions.
Candida are dimorphic fungi presented as commensal yeast carriages or invasive hyphae. The hyphae phenotype is associated with virulence, epithelial infiltration, tissue damage, keratinization, and biofilm formation. Thus, hyphae identification is necessary for detecting oral candidiasis (OC) transition from commensal Candida. Recently, biofilm formation is assumed to have a critical role in OC in addition to hyphae transition. Candida biofilm comprises a sessile-shaped heterogeneous ecosystem, which includes Candida microorganisms, extracellular matrix, and sometimes bacteria. Compared to planktonic Candida, biofilm formation induces persistent infection, recurrence, and antifungal resistance and is essential for Candida pathogenicity in mucosal candidiasis.
We seek partners equally driven to set new benchmarks in antimicrobial advancement and patient outcomes through transformative solutions for these unmet needs.
Join our pioneering team reshaping the next generation of safe and effective anti-biofilm treatments.